- This event has passed.
Cancer Stem Cells and New Treatments (Day 2)
May 22, 2014 @ 6:00 pm - 8:00 pmFree
The Center for Genetic Medicine of Northwestern University welcomes you to attend the Silverstein Lecture Series on May 21 (Chicago) and May 22 (Evanston), featuring Max S. Wicha, MD, Distinguished Professor of Oncology and Director, University of Michigan Comprehensive Cancer Center.
Why do tumors reemerge in so many cancer patients? Current cancer treatments target the cells that make up the bulk of a tumor, but may miss the cells that cause metastasis and relapse. Recent evidence suggests that many cancers, including breast cancer, are driven by a small subpopulation of “cancer stem cells” that are relatively resistant to radiation and chemotherapy. Dr. Wicha will discuss the “cancer stem cell” model and its implications to the biology and treatment of tumors, including the early clinical trials of treatments that specifically target cancer stem cells.
Wednesday, May 21, 6:00 pm
Chicago Campus, Hughes Auditorium, Lurie Medical Research Center, 303 E. Superior Street, Chicago
Thursday, May 22, 6:00pm
Evanston Campus, Abbott Auditorium, Pancoe Life Sciences Pavilion, 2200 Campus Drive, Evanston
Max S. Wicha, MD is the founding and current director of the University of Michigan Comprehensive Cancer Center (UMCCC). He is a leader in breast cancer research and is a pioneer in the field of cancer stem cells. According to the ISI citation index, Dr. Wicha is among the most highly cited investigators in the field. Dr. Wicha’s group was part of the team that first identified breast cancer stem cells, the first such cells identified in solid tumors. His laboratory has identified a number of cancer stem cell markers and developed models to isolate and characterize these cells, models which have been widely utilized in the field. His group has subsequently elucidated a number of intrinsic and extrinsic pathways which regulate stem cell self-renewal and cell fate decisions. These pathways have provided targets for the development of drugs aimed at targeting cancer stem cells.